GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » 12-1 Month Momentum %

Sino Biopharmaceutical (FRA:SMZ1) 12-1 Month Momentum % : 2.06% (As of Dec. 13, 2024)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-13), Sino Biopharmaceutical's 12-1 Month Momentum % is 2.06%.

The industry rank for Sino Biopharmaceutical's 12-1 Month Momentum % or its related term are showing as below:

FRA:SMZ1's 12-1 Month Momentum % is ranked better than
61.87% of 1445 companies
in the Biotechnology industry
Industry Median: -12.3 vs FRA:SMZ1: 2.06

Competitive Comparison of Sino Biopharmaceutical's 12-1 Month Momentum %

For the Biotechnology subindustry, Sino Biopharmaceutical's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's 12-1 Month Momentum % falls into.



Sino Biopharmaceutical  (FRA:SMZ1) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (FRA:SMZ1) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Sino Biopharmaceutical 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

No Headlines